Project Grant R37CA295527
Award Date
1/20/25
Completion Date
12/31/29
Dollars Obligated
$482K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
The National Cancer Institute (NCI) awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the University of Pittsburgh. The project aims to investigate the functional consequences of high glucose culture on adoptive T cell therapies for cancer. Specifically, the research will (1) identify cellular proteins that are differentially O-GlcNAcylated under high glucose conditions and determine if inhibiting O-GlcNAcylation can restore T cell...
The University of Pittsburgh was awarded a $1,271,780 Project Grant by the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), to develop small molecule adaptors for precision control of universal chimeric antigen receptor (CAR) T cell therapy. The project aims to: 1) create small molecule adaptors for targeting universal CARs to multiple antigens, including tumor cells and immunosuppressive cells; 2) enhance CAR targeting specificity using chemical...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $627,272 project grant to The Johns Hopkins University on Feb 24, 2025 to develop and optimize engineered, self-propelled tumor-infiltrating CAR T cells using synthetic cytokine receptors (velocity receptors) to enhance their migration speed and tumor infiltration capabilities. The goal is to improve the efficacy of CAR T cell therapy for treating pancreatic cancer, which has a 5-year survival rate of just ~12%....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to harness B cells after stem cell transplant to produce novel chimeric antigen receptor T-cells (CAR-Ts) for treating hematological malignancies. The $415,257 award to Duke University, a leading research institution, will fund research to clone antibody-producing B cells with tumor-binding potential after hematopoietic stem cell transplantation. The goal is to engineer less toxic and...
The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program 93.395 Cancer Treatment Research (CFDA 93.395), is funding the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The $402,600 award, granted on Apr 3, 2025, supports research by the Sloan-Kettering Institute for Cancer Research to: (1) test the efficacy and...
This Project Grant award of $147,486 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports research at the University of Pittsburgh to investigate the role of altered lipid metabolism in CD8 T cell exhaustion within the tumor microenvironment. The project aims to (1) evaluate the impact of abolishing citrate transport on carbon utilization and effector function of CD8 T cells in the tumor environment, and (2) determine the role of stored lipids in CD8 T cell...